Project Grant R21DA061784
Award Date
9/15/24
Completion Date
8/31/26
Dollars Obligated
$420K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14214, USA
Similar Awards
The National Institute on Drug Abuse (NIDA) awarded a $847,000 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Tennessee Health Science Center in Memphis, TN. The grant, titled "Neuropeptide S Receptor 1 as a Novel Target for Reducing Opioid Self-Administration and Opioid Relapse", aims to investigate the therapeutic potential of the neuropeptide S receptor 1 (NPSR1) in treating opioid use disorder. The research team will leverage...
The $858,600 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to identify and validate G protein-coupled receptors (GPCRs) expressed by somatostatin-expressing inhibitory neurons in the prefrontal cortex as potential targets for developing novel treatments for opioid use disorder (OUD). The research aims to take an unbiased transcriptomics approach to identify GPCR transcripts in these...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $601,612 to the Icahn School of Medicine at Mount Sinai to conduct research on the neural mechanisms underlying opioid tolerance and withdrawal. The research aims to use molecular profiling, viral approaches, and behavioral analysis in mice to examine gene expression and neuronal activity changes in the habenula-interpeduncular nucleus circuit in...
This $1,749,120 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research focused on understanding the underlying neurobiology and behavioral mechanisms driving the incubation of craving for the opioid oxycodone. The research team at Oregon Health & Science University will use an animal model to investigate how specific neural pathways and synaptic plasticity changes in the nucleus...
This $403,542 Project Grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to profile projection-specific proteome changes associated with the incubation of oxycodone craving. The researchers at the University of Maryland, College Park will focus on the orbitofrontal cortex (OFC)-dorsal striatum (DS) projections, examining proteome changes in OFC neuronal somas (Aim 1) and OFC-DS projection-specific synaptoneurosomes...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $275,253 to Epivario Inc. to develop a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). The research aims to screen and evaluate next-generation inhibitors of the metabolic enzyme ACSS2, which has been shown to play a key role in the consolidation of drug-related memories and neuroplasticity. This project...
This $373,181 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to investigate the role of cholinergic interneurons in the ventral tegmental area on opioid-related behaviors. The key objectives are to determine whether mu-opioid receptors on cholinergic interneurons participate in opioid reward, consumption, and withdrawal, and whether these receptors regulate dopamine release during these...
This $399,884 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to identify small molecule compounds that can bind to the GPR26 receptor and potentially treat opioid use disorders (OUDs) without directly targeting opioid receptors. The research strategy leverages DNA-encoded library (DEL) technology to screen over 125 million compounds and identify high-affinity binders to the GPR26 receptor, which is...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $318,402 to North Central College in Naperville, Illinois to conduct research on the cellular and circuit adaptations contributing to the incubation of oxycodone craving. The project aims to characterize the time course and mechanisms by which the drug ketamine can reduce oxycodone craving during withdrawal, with the goal of developing...
The National Institute on Drug Abuse (NIDA) awarded a $1,213,117 federal Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Washington University in St. Louis to conduct research on developing safer opioid analgesics and antagonists. The project aims to achieve functional selectivity of the mu opioid receptor by activating specific G-protein signaling pathways, with the goal of producing analgesia with fewer side effects like respiratory depression and...